ArticleFrontiers in endocrinology2026
Impact of adding r-LH to r-FSH during ovarian stimulation on reproductive outcomes of women with polyendocrine metabolic ovarian syndrome undergoing
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a common endocrine disorder and a leading cause of anovulatory infertility. In women with PMOS, controlled ovarian stimulation (COS) often results in heterogeneous responses, with many oocytes of poor quality and lower fertilization rates. The combined use of recombinant Luteinizing Hormone (r-LH) and recombinant Follicle-Stimulating Hormone (r-FSH) has shown potential to improve Assisted Reproductive Technology (ART) outcomes in specific populations, such as women with hypogonadotropic hypogonadism or advanced age. However, its benefits in women with PMOS remain uncertain. This retrospective cohort study explores whether adding r-LH to r-FSH during COS improves reproductive outcomes in women with PMOS undergoing ART. Results: The study included 156 women diagnosed with PMOS according to Rotterdam criteria, undergoing COS at a single tertiary center. After propensity score matching for age, body mass index (BMI), anti-Müllerian hormone (AMH), LH, and LH/FSH ratio, 106 women were divided into two groups: 53 received r-LH/r-FSH, and 53 received r-FSH alone. Baseline data, stimulation parameters, and ART outcomes were analyzed. Women in the r-LH/r-FSH group required a higher cumulative FSH dose (2932 ± 848 vs. 2455 ± 588IU, p<0.002), produced more follicles on trigger day (13.91 ± 7.45 vs. 10.09 ± 5.55, p=0.014), and had more oocytes injected (13.81 ± 8.01 vs. 11.66 ± 5.57, p=0.0499). Multivariate analysis confirmed r-LH/r-FSH was independently associated with increased follicular recruitment, regardless of AMH levels. However, stimulation protocol was not a significant predictor of oocyte count; age and AMH remained the primary factors. Total FSH dose was not associated with follicle number. No significant differences were observed in cumulative live birth rate; however, clinical pregnancy rate (CPR) after frozen embryo transfer (FET) was higher in the control group (54.5% vs. 25.0%, p=0.043). Conclusion: Adding r-LH to r-FSH during COS in women with PMOS was associated with increased follicular recruitment but did not improve live birth or overall pregnancy rates. Notably, CPR after FET was lower with r-LH/r-FSH. These findings suggest r-LH may modulate ovarian response, but further research is needed to clarify its role in ART protocols. Due to the retrospective, non-randomized design, these results are hypothesis-generating, and routine use of r-LH in this setting cannot currently be recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.